Pluri Inc. Faces Delisting Concerns
Ticker: PLUR · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1158780
| Field | Detail |
|---|---|
| Company | Pluri Inc. (PLUR) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $2,500,000, $35 million, $500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Pluri Inc. might get delisted, check the listing rules.
AI Summary
Pluri Inc. filed an 8-K on July 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event date being July 19, 2024. The company, formerly known as Pluristem Therapeutics Inc., is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This filing indicates potential issues with Pluri Inc.'s continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and future viability.
Key Players & Entities
- Pluri Inc. (company) — Registrant
- Pluristem Therapeutics Inc. (company) — Former company name
- July 19, 2024 (date) — Earliest event date
- July 23, 2024 (date) — Report date
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the specific reason for Pluri Inc.'s potential delisting?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not detail the specific rule or standard not met.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 19, 2024.
What is Pluri Inc.'s former company name?
Pluri Inc. was formerly known as Pluristem Therapeutics Inc.
In which state is Pluri Inc. incorporated?
Pluri Inc. is incorporated in Nevada.
What is the SIC code for Pluri Inc.?
The Standard Industrial Classification (SIC) code for Pluri Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,023 words · 4 min read · ~3 pages · Grade level 16.9 · Accepted 2024-07-23 07:30:34
Key Financial Figures
- $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
- $2,500,000 — es the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued l
- $35 million — value of listed securities of at least $35 million or net income of $500,000 from continui
- $500,000 — f at least $35 million or net income of $500,000 from continuing operations in the most
Filing Documents
- ea0209859-8k_pluri.htm (8-K) — 28KB
- 0001213900-24-063305.txt ( ) — 199KB
- plur-20240719.xsd (EX-101.SCH) — 3KB
- plur-20240719_lab.xml (EX-101.LAB) — 33KB
- plur-20240719_pre.xml (EX-101.PRE) — 22KB
- ea0209859-8k_pluri_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its potentially regaining compliance with Nasdaq's continued listing requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: Pluri may not be able to complete a financing transaction on favorable terms, in a timely manner or at all; changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of P
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: July 23, 2024 By: /s/ Chen Franco-Yehuda Name: Chen Franco-Yehuda Title: Chief Financial Officer 2